Brief: Ascletis Announces U.S. FDA Clearance Of Ind Application For Its Oral Small Molecule Il-17 Inhibitor, ASC50, For The Treatment Of Psoriasis
22/05/2025 12:08
May 22 (Reuters) - Ascletis Pharma Inc 1672.HK: ASCLETIS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ITS ORAL SMALL MOLECULE IL-17 INHIBITOR, ASC50, FOR THE TREATMENT OF PSORIASIS ASCLETIS PHARMA INC - PHASE I TRIAL DOSING EXPECTED TO START IN Q3 2025 Source text: ID:nPn77l9L0a Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026